Vapaliximab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 470629104

| image =

| type = mab

| mab_type = mab

| source = xi/o

| target = VAP-1

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 336801-86-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = M1EGR25LBB

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Vapaliximab is a chimeric monoclonal antibody{{cite journal | journal = WHO Drug Information | volume = 17 | issue = 2 | date = 2003 | title = Recommended INN: List 49 International Nonproprietary Names for Pharmaceutical Substances (INN) | url = https://web.archive.org/web/20091016232326/http://whqlibdoc.who.int/druginfo/INN_2003_list49.pdf }} and an experimental immunosuppressive drug.{{cite journal | vauthors = Panebianco M, Walker L, Marson AG | title = Immunomodulatory interventions for focal epilepsy | journal = The Cochrane Database of Systematic Reviews | volume = 10 | issue = 10 | pages = CD009945 | date = October 2023 | pmid = 37842826 | pmc = 10577807 | doi = 10.1002/14651858.CD009945.pub3 }} Development was discontinued by 2012.{{cite web |title=Vapaliximab | work = AdisInsight | publisher = Springer Nature Switzerland AG |url= https://adisinsight.springer.com/drugs/800017603 | access-date=2 January 2019}}